Ashraf H Abadi
German University in Cairo, Egypt
Title: New erecting perspectives for phosphodiesterase 5 inhibitors
Biography
Biography: Ashraf H Abadi
Abstract
Phosphodiesterase 5 inhibitors are mainly indicated for the treatment of erectile dysfunction. Currently approved compounds differ mainly in their pharmacokinetics profile and propensity to induce side effects caused due to cross inhibition of other PDEs. The mechanism of action of PDE5 inhibitors includes elevating the levels of the universal messenger cGMP in different cells, thus several potential uses and indications are currently emerging including, treatment of pulmonary arterial hypertension, congestive heart failure, Raynaud’s disease, benign prostatic hyperplasia, enhancement of cognitive functions, enhancement of hearing, as well as prevention and treatment of different types of cancer, particularly the colorectal one.
From discovery perspective, a newly emerging class is GAF domain rather than catalytic domain is also emerging. This class shows favorable properties better than classic inhibitors.